Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cyclohexane Carboxamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HSD11B1 known ✓ | P28845 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.55 |
| ▸ | CES1 | P23141 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | NOS2 | P35228 | 2/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclohexane Carboxamide SCHEMBL3244973 | 1.00 | CES2 (0.55) | CES2CES1KDM4EMAPTKMT2A | |
| Cyclohexane Carboxamide SCHEMBL27392487 | 1.00 | CES2 (0.55) | CES2CES1KDM4EMAPTKMT2A | |
| Cyclohexane Carboxamide SCHEMBL28848201 | 0.97 | CES2 (0.52) | CES2CES1KDM4EMAPTKMT2A | |
| SCHEMBL28636550 | 0.97 | CES2 (0.58) | CES2CES1KDM4EMAPTKMT2A | |
| Cyclohexane Carboxamide SCHEMBL26181 | 0.97 | — | — | |
| SCHEMBL25485911 | 0.97 | CES2 (0.58) | CES2CES1KDM4EMAPTKMT2A | |
| SCHEMBL217428 | 0.97 | CES2 (0.58) | CES2CES1KDM4EMAPTKMT2A | |
| SCHEMBL218387 | 0.97 | CES2 (0.58) | CES2CES1KDM4EMAPTKMT2A | |
| SCHEMBL30542351 | 0.97 | CES2 (0.58) | CES2CES1KDM4EMAPTKMT2A | |
| SCHEMBL217106 | 0.97 | CES2 (0.58) | CES2CES1KDM4EMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109790164-B | Purine and 3-deazapurine analogues as choline kinase inhibitors | 内尔维亚诺医疗科学公司 | 2022-01-25 | — | — | CN | claimed |
| CN-109790164-A | Purine and 3- as choline kinase inhibitor remove azepine purine analogue | 内尔维亚诺医疗科学公司 | 2019-05-21 | — | — | CN | claimed |
| EP-2758375-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF | Advinus Therapeutics Limited (IN) | 2014-07-30 | — | — | EP | claimed |
| CN-103958473-A | Amide compound, composition and application thereof | ADVINUS THERAPEUTICS LTD | 2014-07-30 | — | — | CN | claimed |
| WO-2013042139-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2013-03-28 | — | — | WO | claimed |
| CN-100475778-C | Diketohydrazine derivative compound and drug containing the same as active ingredient | ONO PHARMACEUTICAL CO (JP) | 2009-04-08 | — | — | CN | claimed |
| CN-113164481-B | Cycloalkane-1, 3-diamine derivatives | 第一三共株式会社 | 2024-08-30 | — | — | CN | disclosed |
| CN-114341362-B | Preparation method of (R) -1,2,3, 4-tetrahydroisoquinoline-1-carboxylic acid and derivative thereof, and levopraziquantel | 苏州同力生物医药有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-113365969-B | Connector containing phthalic aldehyde and application thereof in preparation of antibody-drug conjugate | 上海药明合联生物技术有限公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-116354957-A | CDK9 inhibitors and uses thereof | 药捷安康(南京)科技股份有限公司 | 2023-06-30 | — | — | CN | disclosed |
| CN-110404073-B | Methods and pharmaceutical compositions for treating hepatitis B virus infection | 国家医疗保健研究所 | 2022-08-16 | — | — | CN | disclosed |
| CN-114786673-A | CDK inhibitors and their use as medicaments | 普莱鲁德疗法有限公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-114555573-A | Prostaglandin E2(PGE2)EP4Receptor antagonists | 多曼治疗学公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2004110992-A2 | PROCESS FOR IMIDAZO[4,5-C] PYRIDIN-4-AMINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-12-23 | — | — | WO | disclosed |
| CN-1535272-A | Nitrogen-containing bicyclic heterocycles | ʷ | 2004-10-06 | — | — | CN | disclosed |
| CN-1444584-A | N- [ 5- [ [ [ 5-alkyl-2-oxazolyl ] methyl ] thio ] -2-thiazolyl ] carboxamide inhibitors of cyclin dependent kinases | BRISTOL MYERS SQUIBB CO (US) | 2003-09-24 | — | — | CN | disclosed |
| CN-1440284-A | Method for preventing and treating alopecia induced by chemotherapy or radiotherapy | BRISTOL MYERS SQUIBB CO (US) | 2003-09-03 | — | — | CN | disclosed |
| CN-1433416-A | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamideinhibitors of cyclin dependent kinases | BRISTOL MYERS SQUIBB CO (US) | 2003-07-30 | — | — | CN | disclosed |
| CN-1066070-A | Promote the new benzo-fused lactams that tethelin discharges | MERCK & CO INC (US) | 1992-11-11 | — | — | CN | disclosed |
| EP-0254327-A2 | N-N-disubstituted-omega-(2-amino-3-(carbonylmethyl)-3,4-dihydroquinazolinyl) oxyalkylamides and related compounds | SYNTEX (U.S.A.) INC. (US) | 1988-01-27 | — | — | EP | disclosed |